Overview

A Pharmacokinetic and Safety Study of Osmotic Release Oral System (OROS) Hydromorphone in Non-Opioid Tolerant Chinese Participants With Cancer

Status:
Completed

Trial end date:
2012-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the single dose pharmacokinetic profile (explores what a drug does to the body) and safety of Osmotic Release Oral System (OROS) hydromorphone in chinese participants with cancer (abnormal tissue that grows and spreads in the body) who are not opioid (morphine-like medications) tolerant (decrease in response to a fixed dosage of drug over time and higher doses of a drug are needed to get desired effect).

Phase:

Phase 1

Details

Lead Sponsor:

Xian-Janssen Pharmaceutical Ltd.

Treatments:

Hydromorphone